GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
TrustPilot
Reema J.
1 个月前
法蒂玛 A.
3天前
维克拉姆·D.
2 周前
Farhan Q.
2 个月前
